Navigation Links
Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model

A just-published research study by Dr. R Preston Mason and colleagues at Elucida Research has determined that astaxanthin, a relatively //unknown carotenoid found in nature, shows significant promise as a viable scaffold for a new therapy to treat cardiovascular disease based on its exceptional antioxidant properties in membrane models.

Combined with published proof-of-concept, pre-clinical and anecdotal human data, the results of the Mason study (Differential effects of carotenoids on lipid peroxidation due to membrane interactions; xray diffraction analysis by McNulty et al.) signify that astaxanthin exhibits potential utility for use as the scaffold for antioxidant/anti-inflammatory agents in the treatment of cardiovascular and other chronic inflammatory diseases. An astaxanthin derivative may improve, or augment, the restoration of the cellular oxidation balance (i.e. redox status) of mitochondria and cell signaling pathways upstream from the point that produces activation of bioactive inflammatory mediators.

"These data clearly demonstrate a differentiation within the carotenoid class of medically promising antioxidants and provided, in part, the impetus for Cardax Pharmaceuticals to advance an astaxanthin-based derivative into an IND development program,” according to Fredric Pashkow, Executive Vice President and Chief Medical Officer of the Company and former head of U.S. Medical Affairs for cardiovascular drugs at Sanofi-Aventis.

Pashkow also said that the work from Mason’s lab suggests astaxanthin could provide a platform for discovery of an entirely new class of safe, cardiovascular drugs. “These potent antioxidants may be the third big wave in the modern therapy for the secondary prevention of heart attack and stroke. In the heart, these agents probably will work by recalibrating the cellular oxidation balance in order to blunt the cell and tissue inflammatory response to injury and limit damage to the myocardium.”

In addition, by limiting the amount of oxidative damage to LDL, the “bad cholesterol,” an astaxanthin derivative could alter the progress of atherosclerosis, the underlying inflammatory process that clogs arteries and is responsible for most heart attacks and strokes when an atherosclerotic plaque ruptures.

Pashkow maintains that statins represented the “first big wave” of cardiovascular preventive therapy. They proved to lower the risk of a second heart attack or cardiovascular death by 45% over 5 years, though more than half of the people treated did not realize their benefit. Increasing the dose of the statin improves the outcome and extends the benefits to people who have risk factors alone such as high cholesterol, but dose limiting side effects emerge especially when the drugs are taken for a long time. Pashkow said that the recent problems encountered with Pfizer’s torcetrapib highlight the impact of a late stage pipeline non-approval combined with the looming patent expiry of the current market leading therapy.

Antiplatelet therapies, particularly aspirin and aspirin in combination with other antiplatelet agents represent the “second big wave” of preventive therapies following a heart attack. In combination, they reduce the risk of future heart attacks and strokes by about 30% over a one-year period.

However, an appreciable segment of the population are 'resistant' to antiplatelet therapy and remain relatively unprotected. More potent antiplatelet therapies, or increased doses of aspirin increase the risk of bleeding. “This wave of treatments,” said Pashkow “may be peaking as well.”

Cardax Pharmaceuticals is exploring the use of astaxanthin and novel astaxanthin derivatives, as well as other carotenoids, for use as medical therapeutics (i.e. antioxidant/anti-inflammatory) in disease states characterized by abnormal cellular oxidation and chronic inflammation (e.g. cardiovascular, liver, ocular, prostatic and neurodegenerative diseases).


Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
Breaking Medicine Technology: